Company / Working Capital
SELLAS Life Sciences Group, Inc. Working Capital History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$6.8M
FY2024
5-year range
-$10.6M / $24.6M
FY2020-FY2024
Trend
+164.5%
vs FY2023
Sector context
#206 of 213
Health Care
What the data says
Among 213 Health Care companies, SELLAS Life Sciences Group, Inc. is in the bottom 3% for working capital. Working Capital returned to growth in FY2024 after 3 years of decline, reaching $7M.
Based on SEC 10-K filings.
$7M in FY2024 with a 5-year CAGR of +18.2%.
Improved from $2M to $7M over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- -27.7%
- 5-Year CAGR
- +18.2%
- 10-Year CAGR
- -
Sector benchmark
Bottom 3% in Health CareTop 97% of 213This company $6.8M Sector average $934.6M
▼
-99.3% below sector average
Key checks
Key Insights
- 5-year CAGR of +18.2%, indicating consistent growth.
- In FY2024, working capital increased 164.5% year-over-year.
- Ranks #206 out of 213 companies in the Health Care sector.
- Peak working capital was recorded in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.39 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $6.8M | +164.5% |
| FY2023 | -$10.6M | -571.4% |
| FY2022 | $2.2M | -87.6% |
| FY2021 | $18.1M | -26.5% |
| FY2020 | $24.6M | +733.0% |
| FY2019 | $3.0M | +2270.6% |
| FY2018 | -$136.0K | +98.8% |
| FY2017 | -$11.5M | -1949.0% |
| FY2016 | $621.0K | +118.0% |
| FY2015 | -$3.5M | -113.9% |
As of FY2024 · SEC 10-K · Updated Jun 30, 2026